Anavex board chair and two other directors resign

The resignations include the Board chair and both departing directors who served on the Audit Committee.

Available on EDGAR 11/02/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:31 PM EST

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Anavex Life Sciences Corp. (AVXL) reported that Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from its Board effective October 28, 2026. Dr. Ma had served as Board chair and an Audit Committee member; Mr. Patel had served on the Audit Committee, while Dr. Senderowicz was not serving on a Board committee.

Dr. Ma said her views about the Company’s strategic direction were not fully aligned with the Board and management. Mr. Patel and Dr. Senderowicz said their personal views on the Company’s strategy to execute its business plan did not sufficiently align with the Board and management. On November 1, 2026, the Board approved reconstitution of its three standing committees.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

How the balance works

Positive

None.

Negative

Moderate pointThree directors, including the Board chair, resigned effective October 28, 2026.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Departing directors: 3 directors Standing committees: 3 committees Resignation effective date: October 28, 2026 +1 more

4 metrics

Departing directors 3 directors Board resignations effective October 28, 2026.

Standing committees 3 committees The Board approved their reconstitution on November 1, 2026.

Resignation effective date October 28, 2026 Effective date for the three Board resignations.

Committee reconstitution approval date November 1, 2026 Board approval of reconstitution of its three standing committees.

Key Terms

Audit Committee, standing committees, reconstitution

3 terms

Audit Committee technical

"a member of the Audit Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

standing committees technical

"reconstitution of its three standing committees"

reconstitution technical

"approved the reconstitution of its three standing committees"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which AVXL directors resigned from the board?

Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned effective October 28, 2026. Dr. Ma was Board chair and an Audit Committee member, Mr. Patel was an Audit Committee member, and Dr. Senderowicz served on no Board committees.

Why did AVXL directors resign?

Dr. Ma stated that her views about the Company’s strategic direction were not fully aligned with the Board and management. Mr. Patel and Dr. Senderowicz said their personal views about the Company’s strategy to execute its business plan did not sufficiently align with the Board and management.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2026

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada	001-37606	98-0608404
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

630 5th Avenue, 20th Floor, New York, NY USA 10111

(Address of principal executive offices) (Zip Code)

1-844-689-3939

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AVXL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 28, 2026, each of Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the Board of Directors (“Board”) of Anavex Life Sciences Corp. (“Anavex” or the “Company”) effective as of October 28, 2026. Prior to such resignations, Dr. Ma served as the Chair of the Board and a member of the Audit Committee of the Board, Mr. Patel served as a member of the Audit Committee of the Board and Dr. Senderowicz was not serving on any Board committees.

As stated in Dr. Ma’s resignation letter, Dr. Ma has decided that her views about the Company’s strategic direction are not fully aligned with those of the Board and management.

As stated in Mr. Patel’s resignation letter, Mr. Patel has concluded that his personal views regarding the Company’s strategy to execute its business plan do not sufficiently align with those of the Board and management.

As stated in Dr. Senderowicz’s resignation letter, Dr. Senderowicz has concluded that his personal views regarding the Company’s strategy to execute its business plan do not sufficiently align with those of the Board and management.

The descriptions of the resignation letters of Dr. Ma, Mr. Patel and Dr. Senderowicz set forth in this Item 5.02 are qualified in their entireties by the full text of the resignation letters of Dr. Ma, Mr. Patel and Dr. Senderowicz, which are filed as Exhibits 17.1, 17.2 and 17.3, respectively, to this Current Report on Form 8-K and incorporated by reference into this Item 5.02.

The Company furnished Dr. Ma, Mr. Patel and Dr. Senderowicz with a copy of the disclosures in this Item 5.02 no later than the date of the filing of this Current Report on Form 8-K with the Securities and Exchange Commission, providing each of them with the opportunity to furnish the Company with a letter addressed to the Company stating whether she or he agrees with the statements made by the Company herein and, if not, stating the respects in which he or she does not agree. The Company will file any letter received by it from Dr. Ma, Mr. Patel and/or Dr. Senderowicz as an exhibit to an amendment to this Form 8-K within two business days after receipt by the Company.

Item 8.01. Other Events.

On November 1, 2026, the Board approved the reconstitution of its three standing committees as reflected below:

●

Audit Committee: Dr. Claus van der Velden (Chair), Dr. Peter Donhauser and Dr. Axel Paeger

●

Compensation Committee: Dr. Peter Donhauser (Chair) and Dr. Claus van der Velden

●

Nominating & Corporate Governance Committee: Dr. Axel Paeger (Chair) and Dr. Peter Donhauser

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
17.1		Resignation Letter of Jiong Ma, dated October 28, 2026, to the Board of Directors of Anavex Life Sciences Corp.
17.2		Resignation Letter of Gautam Patel, dated October 28, 2026, to the Board of Directors of Anavex Life Sciences Corp.
17.3		Resignation Letter of Adrian Senderowicz, dated October 28, 2026, to the Board of Directors of Anavex Life Sciences Corp.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANAVEX LIFE SCIENCES CORP.

	/s/ Sandra Boenisch
	Name: Sandra Boenisch, CPA, CGA
	Title: Principal Financial Officer, Treasurer

Date: November 2, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents